Tamoxifen Raloxifene Anastrozole Incidence of BC reduced by 50 26, 959 77, 256 13, 338 Incidence of BC increased by 100 797 16, 271 3, 358 Treatment relative risks for breast cancer incidence set to lower 95 CI 5, 031 73, 744 1, 032 Treatment relative risks for breast cancer incidence set to upper 95 CI 19, 536 22, 858 16, 492 Adherence set to 100 6, 109 27, 956 561 Adherence set to 25 16, 601 53, 787 8, 064 Incidence of adverse events reduced by 50 9, 607 37, 296 2, 174 Incidence of adverse events increased by 100 9, 588 35, 028 2, 610 Treatment relative risks of adverse events set to lower 95 CI 8, 856 37, 878 1, 648 Treatment relative risks of adverse events set to upper 95 CI 10, 572 35, 597 3, 356 Costs of treatment reduced by 50 6, 409 27, 227 1, 490 Costs of treatment increased by 100 16, 001 55, 246 3, 962 Costs of adverse events reduced by 50 9, 604 37, 284 2, 176 Costs of adverse events increased by 100 9, 609 35, 130 2, 591 Costs of breast cancer reduced by 50 14, 529 41, 504 7, 220 Costs of breast cancer increased by 100 240 26, 691 7, 497 Relative risks of adverse events persist for 20 years after end of treatment 10, 146 35, 786 2, 493 Breast cancer treatment is associated with no chemotherapy costs 10, 146 35, 786 2, 493 Relative risks for raloxifene taken from the RUTH trial 4, 959 finasteride 1 mg cheap buy